tiprankstipranks
Trending News
More News >

COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays

Story Highlights
COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays

An announcement from COSCIENS Biopharma ( (TSE:CSCI) ) is now available.

COSCIENS Biopharma Inc. has announced the acceptance of a management cease trade order (MCTO) by the Ontario Securities Commission due to a potential delay in filing its annual financial statements and related documents. The MCTO restricts trading by the company’s CEO and CFO but does not affect other shareholders. COSCIENS is working diligently to complete the filings by April 7, 2025, and will issue bi-weekly updates until the filings are complete. The delay will not impact the company’s stock listing on the Nasdaq Capital Market.

More about COSCIENS Biopharma

COSCIENS Biopharma Inc. is a life science company that develops and commercializes a diverse range of cosmeceutical, nutraceutical, and pharmaceutical products. The company focuses on leveraging proprietary extraction technology to produce active ingredients from renewable plant resources, which are used in popular skincare brands and are being developed for potential nutraceutical and pharmaceutical applications.

YTD Price Performance: 3.30%

Average Trading Volume: 25,857

Technical Sentiment Signal: Buy

Current Market Cap: $9.33M

See more data about CSCI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App